Asahi shares mark weekly slide after cyberattack halts production
MONTREAL - ZYUS Life Sciences Corporation (TSXV:ZYUS), trading at $9.83 with a notable dividend yield of 5.27%, announced Tuesday it has activated its first clinical site and enrolled the first patient in its Phase 2a UTOPIA-1 cancer pain trial at the Centre Hospitalier de l’Université de Montréal (CHUM).
The single-arm, proof-of-concept study aims to investigate the safety and preliminary analgesic efficacy of Trichomylin softgel capsules in patients with advanced cancer experiencing moderate to severe cancer-related pain.
CHUM continues to actively recruit additional patients for the trial, which represents a step forward in the company’s clinical development program for non-opioid pain management solutions.
"Trichomylin softgel capsules are designed to bridge the treatment gap between conventional therapies such as opioids and NSAIDs, offering a differentiated, evidence-based pharmaceutical approach for cancer pain," said Brent Zettl, President and CEO of ZYUS Life Sciences, according to the company’s press release.
ZYUS is focused on developing cannabinoid-based pharmaceutical drug candidates for pain management. The UTOPIA-1 trial is registered on clinicaltrials.gov with the identifier NCT06533657.
The company states it aims to generate clinical data to evaluate this potential new therapy for cancer pain. ZYUS is listed on the TSX Venture Exchange under the ticker symbol ZYUS, with a P/E ratio of 16.17 and an impressive 11-year track record of consecutive dividend payments. For deeper insights into ZYUS’s financial metrics and additional analysis, explore InvestingPro, which offers exclusive financial health indicators and investment recommendations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.